Hot Growth Special Report 2006 >



Endo Pharmaceuticals Holdings (ENDP)

When Endo got its pain-relieving patch Lidoderm approved by the U.S. Food & Drug Administration in 1999, the pharmaceutical company thought it would address a tiny market of 200,000 people who suffer pain related to shingles. But the product has been snapped up by everyone from weekend warriors with occasional back pain to office workers who have carpal tunnel syndrome. Clearly pain pays: In the quarter ended Mar. 31, Endo reported 48% sales growth and 50% earnings per share growth. The company expects sales of Lidoderm to skyrocket 26%, to at least $530 million. Endo is working on several other pain-relieving products, hoping to address a range of age and disease-related disorders, including cancer and neuropathic pain.

Company Info

2005 Rank


Market Value*
($ Millions)


($ Millions)


Sales Growth
(3-yr. avg. annual)

24.5 %

($ Millions)


Profit Growth
(3-yr. avg. annual)

89.0 %

Return on Inv. Capital (3-yr.)

19.2 %

Share Price
12-Mo. Hi/Lo


Share Price
As of 4/28/06


Return on Equity

22.9 %

P/E Ratio


No. of Employees


Industry Pharmaceuticals


Location Chadds Ford, Pa.
Phone 610 558-9800
*Trailing 12 months
Stock price data as of 4/28/06
DATA: Standard & Poor's Compustat

Related Articles

Endo: The Pain and the Gain

No Pain, Some Gain

Hey, You Don't Look So Good

There's Entrancing News About Hypnosis

Company Snapshot

Endo Pharmaceuticals Holdings engages in the research, development, sale, and marketing of prescription pharmaceuticals to treat and manage pain. Its products include Lidoderm for the relief of the pain associated with post-herpetic neuralgia; Percocet, Percodan, and OxyContin to treat moderate-to-moderately severe pain; Frova to prevent menstrual migraine; Synera, a topical local anesthetic patch to provide local dermal anesthesia in children and adults. The company's generic pharmaceuticals comprise Endocet, a generic oxycodone hydrochloride and acetaminophen product; and morphine sulfate extended-release tablets for pain management. Its pipeline portfolio includes Oxymorphone ER and IR tablets to treat acute post-operative pain; Frova MM in Phase III clinical trial development to treat menstrual migraine; Rapinyl tablet in Phase III clinical trial development to treat breakthrough cancer pain; Chronogesic in Phase II development to treat patients with opioid responsive chronic pain; and Transdermal Sufentanil Patch in early-stage clinical development to provide relief of moderate-to-severe chronic pain. The company's pipeline portfolio also includes Topical Ketoprofen Patch in Phase II clinical trials to treat acute pain associated with soft-tissue injuries; LidoPAIN BP in Phase II clinical trial development to treat acute lower back pain; and Propofol IDD-D that is at the end of Phase II clinical trial development to maintain anesthesia in adults during surgery and for sedation of adults hospitalized in an intensive-care setting. It serves physicians in pain management, neurology, surgery, anesthesiology, oncology, and primary care, as well as serves retail pharmacies and other health-care professionals through wholesale drug distributors in the U.S. The company has strategic alliances with SkyePharma and Penwest Pharmaceuticals. Endo Pharmaceuticals Holdings was incorporated in 1997 and has its headquarters in Chadds Ford, Pa.

Data provided by Capital IQ
Peter A. Lankau

Peter A. Lankau, 53

Chief Executive Officer, President and Director

Total Compensation*

$ 813,354

Total Options Value*

$ 19,466,587

* Fiscal Year 2005

Executive Bio

Peter Lankau has been CEO and president of Endo Pharmaceuticals Holdings and Endo Pharmaceuticals since May, 2005. Lankau served as chief operating officer of Endo Pharmaceuticals Holdings from April, 2003, to May, 2005. From June, 2000, to April, 2003, Lankau served as senior vice-president, U.S. business, of Endo. Prior to joining Endo in June, 2000, Lankau was vice-president, sales and marketing, for Alpharma USPD, in Baltimore. He served as vice-president, sales, U.S. pharmaceuticals, for Aventis Pharmaceuticals from 1996 to 1999. Lankau was executive director, strategy and development, for Aventis from 1995 to 1996. Prior to 1995, he held various management positions at Aventis, including business unit management, and had responsibility for Aventis generics business as well as managed care. He has been a director of Endo Pharmaceuticals Holdings since March, 2005.

Management Team

Key Executives

Peter A. Lankau; Jeffrey R. Black; David A. H. Lee.; Caroline B. Manogue

Board Directors

Carol A. Ammon; Peter A. Lankau; Michael Hyatt; Roger H. Kimmel; Joseph T. ODonnell; Clive A. Meanwell; John Delucca; Michel de Rosen

Executive Data provided by Capital IQ